2024 Targeted Therapies for Lung Cancer (TTLC) - Abstracts & Posters-PP01.22 Arter

PP01.22 Arter - Abstract

Pdf Summary

The study focused on BRAF mutated Non-Small Cell Lung Cancer (NSCLC) divided into three classes, with only class I having FDA-approved treatments. Utilizing the AACR GENIE database, the researchers identified a bimodal distribution of tumor mutation burden (TMB) among all three classes. Out of 20,713 NSCLC patients, 1.6% were in class I, 1.3% in class II, and 1.1% in class III. Analysis revealed demographic differences among the classes, with varying TMB levels. The median TMB for class I, II, and III BRAF NSCLC was 6.5, 9.5, and 10.3 respectively. A significant proportion of patients in all classes had TMB levels over 10, indicating high heterogeneity within each class. Class III exhibited the highest median TMB, followed by class II and then class I. The distribution of specific BRAF mutations varied across the classes as well. This comprehensive survey highlights the molecular distinctions within the BRAF mutated NSCLC classes, emphasizing the importance of considering TMB in the management of these patients.

Keywords

BRAF mutated Non-Small Cell Lung Cancer

NSCLC

FDA-approved treatments

AACR GENIE database

tumor mutation burden

demographic differences

median TMB

high heterogeneity

specific BRAF mutations

molecular distinctions